Title

Phase 2 Trial of Obinutuzumab, a Humanized, Glycoengineered Monoclonal CD20 Antibody, in Combination with Ifosfamide, Carboplatin and Etoposide for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Document Type

Abstract

Publication Date

9-2018

Department

Pediatrics

Second Department

Health Behavior and Community Health

This document is currently not available here.

Share

COinS